CagriSema 0.25 mg: Dosing Guide & What to Expect

CagriSema 0.25 mg is a starting dose for this investigational medication. Understanding what to expect at this dose level helps patients and clinicians make informed decisions about treatment progression.

What Is CagriSema 0.25 mg?

CagriSema (Cagrilintide + Semaglutide (combination)) is a GLP-1 receptor agonist + Amylin analog (cagrilintide) administered by weekly subcutaneous injection. The 0.25 mg dose is the starting dose in the standard titration protocol, designed to minimize early side effects while establishing receptor engagement.

Clinical trial data from REDEFINE-1 demonstrates a mean weight loss of approximately 22.7% at the maximum dose (2.4 mg) in trial-eligible participants. Results at intermediate doses like 0.25 mg are typically lower.

Titration Schedule for CagriSema

Patients typically remain at 0.25 mg for 4 weeks before escalating to CagriSema 0.5 mg, assuming the dose is well tolerated.

Side Effects at 0.25 mg

The most commonly reported side effects of CagriSema include GI-related symptoms that tend to be most pronounced during dose escalation. At 0.25 mg (the starting dose), side effects are typically mild to moderate as your body adjusts to the medication.

• •Nausea
• •Vomiting
• •Diarrhea
• •Constipation
• •Injection Site Reaction
• •Fatigue
• •Headache

Most side effects are transient and improve within 2–4 weeks at a stable dose. GI symptoms (nausea, diarrhea, constipation) are the most common reasons for dose reduction or discontinuation.

When to Call Your Doctor

• Persistent vomiting preventing adequate hydration
• Severe abdominal pain that does not resolve
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Any signs of allergic reaction
• Heart rate increase of >20 bpm at rest that persists

When to Escalate from 0.25 mg

Standard protocol calls for 4 weeks at each dose level before escalation, provided the dose is well tolerated. If side effects are significant, your prescriber may recommend staying at 0.25 mg for an additional 4 weeks (an 8-week interval) before moving up.

Do not escalate doses without prescriber guidance. Self-directed dose escalation increases the risk of adverse events.

Contraindications & Safety

This medication is investigational and not approved for clinical use outside of clinical trials. Key contraindications include:

• Investigational combination — contraindications not yet fully established
• Similar profile to semaglutide expected

Pregnancy: Investigational — not established. Discuss with your prescriber if pregnancy is a possibility.